Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Announces Positive Initial Findings for Atumelnant at ENDO 2024
Summary
On June 3, 2024, Crinetics Pharmaceuticals, Inc. announced positive initial findings from its development program for atumelnant (CRN04894), a novel oral ACTH receptor antagonist, in two ongoing studies for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's Syndrome (ADCS). In the CAH study, 100% of participants maintained androstenedione levels below the upper limit of normal, with a 96% reduction at 12 weeks. In the ADCS study, all participants normalized 24-hr urinary free cortisol levels within 10 days of treatment. No severe adverse events were reported, and the most common mild to moderate side effects included fatigue, headache, and upper respiratory tract infection. These findings were presented at the Endocrine Society's Annual Meeting (ENDO 2024).
Profitelligence Alerts
Get alerts for CRNX
Be first to know when Crinetics Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (3)
Advertisement
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.
Official SEC Documents
Advertisement